(FM) Inmunología
Departamento académico
Josep
Tabernero Caturla
Publicaciones en las que colabora con Josep Tabernero Caturla (7)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
2022
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
2018
-
Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174
2017
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97